The Horrible History of Big Pharma – Global Research


31-05-21 01:53:00, Important Study by Global Justice Now. “Why we can’t leave pharmaceutical corporations in the driving seat of the Covid-19 response”

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version). 

Visit and follow us on Instagram at @crg_globalresearch.


Executive summary

Any long-term solution to the deadly Covid-19 pandemic involves the discovery and equitable distribution of an effective vaccine and treatment options. Yet, across the world, governments are handing responsibility for Covid-19 solutions over to big pharmaceutical firms, who have a long track record of prioritising corporate profit over people’s health.

The pharmaceutical industry is one of the biggest and most profitable in the world. Many of the individual corporations that constitute ‘Big Pharma’ enjoy annual revenues well in excess of the majority of countries on the planet. Judged by revenue, Johnson & Johnson is wealthier than even rich countries like New Zealand and Hungary. Pfizer’s revenues are bigger than oil-rich Kuwait or Malaysia.

Leaving Moderna aside, which currently has no products on the market, the six other giant corporations covered in this report made combined revenues of $266 billion last year, with profits of $46 billion. Consider these figures in comparison with the US’s unprecedented programme of public spending on vaccine development, which could reach $18 billion,[1] but is currently at around £11 billion, most of which has been handed over to the same rich corporations detailed in this report.[2]

Many commentators look at the work of some of these corporations in 2020 – developing vaccines at breakneck speed – and conclude that, whatever the problems with ‘Big Pharma’, they have nearly delivered the goods.

But this is to miss many important elements of the story which, when taken together, show that the current pharmaceutical model is actually deeply flawed, with its drive to make sky-high returns to shareholders, not a healthier population. The pursuit for very high returns incentivises the most appalling behaviour.

The cases we examine include:

GlaxoSmithKlein (GSK) which, less than ten years ago, was handed a $3 billion fine after it admitted to giving kickbacks to doctors in the US and encouraging the prescription of unsuitable antidepressants to children.[3] Doctors and their spouses were flown to five-star resorts,

 » Lees verder

%d bloggers liken dit: